Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cancer biology finds itself in a post-genomic era and the hopes of using inherited genetic variants to improve prevention and treatment strategies are widespread. One of the largest types of inherited genetic variation is the single nucleotide polymorphism (SNP), of which there are at least 4.5 million. The challenge now becomes how to discover which polymorphisms alter cancer in humans and how to begin to understand their mechanism of action. In this report, a series of recent publications will be reviewed that have studied a polymorphism in the p53 tumor suppressor pathway, MDM2 SNP309. These reports have lent insights into how germline genetic variants of the p53 pathway could interact with gender, environmental stresses and tumor genetics to affect cancer in humans. Importantly, these observations have also exposed potential nodes of intervention, which could prove valuable in both the prevention and treatment of this disease in humans.

Original publication

DOI

10.1038/sj.onc.1210199

Type

Journal article

Journal

Oncogene

Publication Date

26/02/2007

Volume

26

Pages

1317 - 1323

Keywords

Estrogens, Female, Humans, Male, Mutation, Neoplasms, Oxidative Stress, Polymorphism, Single Nucleotide, Proto-Oncogene Proteins c-mdm2, Sex Factors, Signal Transduction, Smoking, Tumor Suppressor Protein p53, Virus Diseases